In Silico Identification of New Anti-SARS-CoV-2 Main Protease (Mpro) Molecules with Pharmacokinetic Properties from Natural Sources Using Molecular Dynamics (MD) Simulations and Hi... by Harrison Onyango, Patrick Odhiambo, David Angwenyi, Patrick Okoth

“…Compounds such as cinanserin, nelfinavir, baicalin, baicalein, candesartan cilexetil, chloroquine, dipyridamole, and hydroxychloroquine have the ability to prevent SARS-CoV-2 Mpro from facilitating COVID 19 infection; thus, they treat COVID 19. …”
Get full text

Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study by Avinash Jain, Vineeta Shobha, S Chandrashekara, Padmanabha Shenoy, Sapan C Pandya, Prakash Chotalia, Sharath Kumar, Sourabh Malviya, Yogesh Preet Singh, Abhishek Patil, Vikas Gupta, Puja Srivastava, Vijaya Prasanna Parimi, Chanakya Kodishala, Ramya Janardana, Benzeeta Pinto, Sudhir Bhandari, Govind Rankawat, Praveen Pratap Jadhav, Damodaram Potugari, Vishnu Sharma, Alpana Parmar, Sunitha Kayidhi, Paul T Antony, Ashish Badika, Amit Sharma

“…Most common medications at the time of COVID diagnosis were steroids (57.76%) and hydroxychloroquine (67.34%). Fever and cough were the most common symptoms. …”
Get full text

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: a retrospective study by Prem Chandra, Vamanjore A Naushad, Nishan K Purayil, Abazar Ahmad M Saeed, Pradeep Radhakrishnan, Irfan Varikkodan, Joe V Mathew, Jaseem Sirajudeen, Riyadh A Hammamy, Ahmad M Badi, Aasir M Suliman, Mohamed N Badawi, Saket Arya, Maryam AlMotawa, Aisha Al-Baker, Rania Alatom, Anand Kartha

“…More patients received hydroxychloroquine and antibiotics during the first wave and more received steroids, antivirals and interleukin-1 antagonist during the second wave. …”
Get full text

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults by Florence Ader, Jean-François Timsit, Yazdan Yazdanpanah, François-Xavier Lescure, Laetitia Moinot, Christelle Delmas, Hélène Espérou, Laurent Abel, Benjamin Leveau, Vinca Icard, Toni Alfaiate, Linda Wittkop, Charles Burdet, France Mentré, Marion Schneider, Nathan Peiffer-Smadja, Julien Poissy, Lila Bouadma, Bruno Lina, Florence Morfin-Sherpa, Maude Bouscambert, Alexandre Gaymard, Gilles Peytavin, Jeremie Guedj, Claire Andrejak, Cedric Laouenan, Drifa Belhadi, Axelle Dupont, Basma Basli, Anissa Chair, Samira Laribi, Julie Level, Marie-Capucine Tellier, Aline Dechanet, Dominique Costagliola, Sandrine Couffin-Cadiergues, Juliette Saillard, Claire Fougerou, Carole Cagnot, Soizic Le Mestre, Delphine Lebrasseur-Longuet, Ventzislava Petrov-Sanchez, Alpha Diallo, NoéMie Mercier, Sarah Tubiana, Benjamin Hamze, Ambre Gelley, Marion Noret, Eric D’Ortenzio, Oriane Puechal, Caroline Semaille

“…The objective of the trial is to evaluate the clinical efficacy and safety of different investigational re-purposed therapeutics relative to Standard of Care (SoC) in patients hospitalised with COVID-19.Methods and analysis DisCoVeRy is a phase III, open-label, adaptive, controlled, multicentre clinical trial in which hospitalised patients with COVID-19 in need of oxygen therapy are randomised between five arms: (1) a control group managed with SoC and four therapeutic arms with re-purposed antiviral agents: (2) remdesivir + SoC, (3) lopinavir/ritonavir + SoC, (4) lopinavir/ritonavir associated with interferon (IFN)-β−1a + SoC and (5) hydroxychloroquine + SoC. The primary endpoint is the clinical status at Day 15 on the 7-point ordinal scale of the WHO Master Protocol (V.3.0, 3 March 2020). …”
Get full text

Serum lipid profile in systemic lupus erythematosus by Jingxiu Xuan, Jingxiu Xuan, Jingxiu Xuan, Chaoqiong Deng, Huiqin Lu, Yan He, Yan He, Yan He, Jimin Zhang, Xiaoli Zeng, Xiaoli Zeng, Yuechi Sun, Yuechi Sun, Yuechi Sun, Shiju Chen, Shiju Chen, Shiju Chen, Yuan Liu, Yuan Liu, Yuan Liu

“…Patients with SLE who took glucocorticoids (GCs) may have experienced increases in TC and TG, while those who took hydroxychloroquine (HCQ) may have experienced increases in TC and HDL. …”
Get full text

Pratiques de l’automédication à l’ère de la pandémie COVID-19 dans trois villes de l’Ouest algérien [Practices of self-medication in the COVID-19 pandemic era in three cities of We... by Derouicha Matmou, Asma Memou, Yassine Merad, Ayoub Bouzid, Sohaïb Abd-El-Koudous Bouzid, Aissa Brik, Mounia Sakouhi

“…Parace­tamol (83.67%) was the most consumed, followed by azithromycin (36.73%), prednisolone (31.10%),amoxicillin_clavulanic acid (30.53%), zinc (27.38%), vitamin C (27.08 %), vitamin D(16.31%), magnesium(12.92%),and even hydroxychloroquine(25.56%). Conclusion- Abuse and misuse of several drugs have been observed, efforts must be made to reduce the risk of self-medication by actively involving pharmacists in therapeutic patient education. …”
Get full text

Pratiques de l’automédication à l’ère de la pandémie COVID-19 dans trois villes de l’Ouest algérien [Practices of self-medication in the COVID-19 pandemic era in three cities of We... by Derouicha Matmou, Asma Memou, Yassine Merad, Ayoub Bouzid, Sohaïb Abd-El-Koudous Bouzid, Aissa Brik, Mounia Sakouhi

“…Parace­tamol (83.67%) was the most consumed, followed by azithromycin (36.73%), prednisolone (31.10%),amoxicillin_clavulanic acid (30.53%), zinc (27.38%), vitamin C (27.08 %), vitamin D(16.31%), magnesium(12.92%),and even hydroxychloroquine(25.56%). Conclusion- Abuse and misuse of several drugs have been observed, efforts must be made to reduce the risk of self-medication by actively involving pharmacists in therapeutic patient education. …”
Get full text